LivaNova (NASDAQ:LIVN) Given New $93.00 Price Target at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its target price upped by analysts at Needham & Company LLC from $81.00 to $93.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 22.63% from the company’s current price.

Other research analysts have also recently issued reports about the company. KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Zacks Research raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Freedom Capital raised shares of LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Barclays lifted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, Robert W. Baird reduced their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and an average target price of $82.88.

LivaNova Stock Performance

LIVN traded down $9.48 during midday trading on Wednesday, reaching $75.84. The company’s stock had a trading volume of 981,432 shares, compared to its average volume of 771,351. LivaNova has a twelve month low of $45.64 and a twelve month high of $85.76. The stock has a market cap of $4.17 billion, a P/E ratio of 38.63 and a beta of 0.86. The company has a fifty day simple moving average of $79.46 and a 200 day simple moving average of $70.51. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.17. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $390.54 million for the quarter, compared to analyst estimates of $380.50 million. During the same quarter last year, the firm earned $1.05 EPS. LivaNova’s quarterly revenue was up 10.8% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Research analysts expect that LivaNova will post 3.73 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.35% of the stock is currently owned by company insiders.

Institutional Trading of LivaNova

Several hedge funds have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. increased its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares during the period. State of Wyoming bought a new position in shares of LivaNova in the second quarter worth $31,000. Quarry LP acquired a new stake in LivaNova during the third quarter worth about $36,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares in the last quarter. Finally, Covestor Ltd increased its position in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after acquiring an additional 392 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates. LivaNova reported adjusted earnings of $1.26 per share, above the $1.08-$1.09 analyst consensus and up from $1.05 a year earlier. Revenue rose 10.8% year over year to $390.54 million, exceeding expectations of approximately $380.50 million. LivaNova Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its full-year earnings outlook. FY 2026 EPS guidance was set at $4.30-$4.40, above the $4.15 consensus estimate. Revenue guidance of roughly $1.5 billion was maintained in line with analyst expectations. LivaNova exceeds second-quarter forecasts and increases 2026 outlook
• Neutral Sentiment: The shares recently hit a fresh 52-week high. The strong rally leading into the earnings announcement may have raised investor expectations and increased the potential for profit-taking, even after the earnings beat. LivaNova Hits Fresh High
• Negative Sentiment: Valuation may be contributing to the weaker reaction. With LivaNova trading near its yearly high and at approximately 38.6 times earnings, investors may be demanding stronger guidance or additional upside beyond the reported beats. The revenue outlook was merely in line with consensus, which may have limited enthusiasm.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.